67.7 USD
-1.25 (-1.81%)
67.7 USD
0 (0%)
HALO gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. While HALO has a great profitability rating, there are some minor concerns on its financial health. HALO is evaluated to be cheap and growing strongly. This does not happen too often! These ratings could make HALO a good candidate for value and growth investing.
1. Profitability
1.1 Basic Checks
HALO had positive earnings in the past year.
HALO had a positive operating cash flow in the past year.
In the past 5 years HALO has always been profitable.
Each year in the past 5 years HALO had a positive operating cash flow.
1.2 Ratios
HALO has a better Return On Assets (26.81%) than 97.55% of its industry peers.
HALO's Return On Equity of 118.17% is amongst the best of the industry. HALO outperforms 99.62% of its industry peers.
The Return On Invested Capital of HALO (42.77%) is better than 99.25% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for HALO is in line with the industry average of 18.22%.
The 3 year average ROIC (17.81%) for HALO is below the current ROIC(42.77%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROIC | 42.77% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
1.3 Margins
The Profit Margin of HALO (47.91%) is better than 98.11% of its industry peers.
In the last couple of years the Profit Margin of HALO has declined.
With an excellent Operating Margin value of 59.33%, HALO belongs to the best of the industry, outperforming 99.81% of the companies in the same industry.
In the last couple of years the Operating Margin of HALO has declined.
Looking at the Gross Margin, with a value of 84.55%, HALO belongs to the top of the industry, outperforming 87.17% of the companies in the same industry.
In the last couple of years the Gross Margin of HALO has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% |
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), HALO is creating value.
Compared to 1 year ago, HALO has less shares outstanding
HALO has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, HALO has an improved debt to assets ratio.
2.2 Solvency
HALO has an Altman-Z score of 5.07. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
HALO has a Altman-Z score of 5.07. This is in the better half of the industry: HALO outperforms 73.40% of its industry peers.
The Debt to FCF ratio of HALO is 2.51, which is a good value as it means it would take HALO, 2.51 years of fcf income to pay off all of its debts.
HALO has a Debt to FCF ratio of 2.51. This is amongst the best in the industry. HALO outperforms 93.40% of its industry peers.
A Debt/Equity ratio of 1.59 is on the high side and indicates that HALO has dependencies on debt financing.
HALO has a worse Debt to Equity ratio (1.59) than 78.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Altman-Z | 5.07 |
ROIC/WACC5.45
WACC7.85%
2.3 Liquidity
HALO has a Current Ratio of 1.59. This is a normal value and indicates that HALO is financially healthy and should not expect problems in meeting its short term obligations.
HALO's Current ratio of 1.59 is on the low side compared to the rest of the industry. HALO is outperformed by 81.13% of its industry peers.
A Quick Ratio of 1.37 indicates that HALO should not have too much problems paying its short term obligations.
HALO's Quick ratio of 1.37 is on the low side compared to the rest of the industry. HALO is outperformed by 82.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 |
3. Growth
3.1 Past
HALO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.55%, which is quite impressive.
HALO shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 30.12% yearly.
HALO shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.19%.
The Revenue has been growing by 38.95% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
3.2 Future
The Earnings Per Share is expected to grow by 17.25% on average over the next years. This is quite good.
The Revenue is expected to grow by 12.82% on average over the next years. This is quite good.
EPS Next Y51.29%
EPS Next 2Y40.02%
EPS Next 3Y32.08%
EPS Next 5Y17.25%
Revenue Next Year33.82%
Revenue Next 2Y29.25%
Revenue Next 3Y23.48%
Revenue Next 5Y12.82%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 12.02, HALO is valued correctly.
Based on the Price/Earnings ratio, HALO is valued cheaper than 96.98% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.77, HALO is valued rather cheaply.
The Price/Forward Earnings ratio is 8.16, which indicates a very decent valuation of HALO.
HALO's Price/Forward Earnings ratio is rather cheap when compared to the industry. HALO is cheaper than 98.87% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of HALO to the average of the S&P500 Index (23.35), we can say HALO is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.02 | ||
| Fwd PE | 8.16 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HALO is valued cheaper than 96.79% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, HALO is valued cheaper than 97.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.22 | ||
| EV/EBITDA | 10.54 |
4.3 Compensation for Growth
HALO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HALO has an outstanding profitability rating, which may justify a higher PE ratio.
HALO's earnings are expected to grow with 32.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.23
PEG (5Y)N/A
EPS Next 2Y40.02%
EPS Next 3Y32.08%
5. Dividend
5.1 Amount
No dividends for HALO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
67.7
-1.25 (-1.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.69%
Inst Owner Change15.59%
Ins Owners0.83%
Ins Owner Change-0.65%
Market Cap7.96B
Revenue(TTM)1.24B
Net Income(TTM)595.49M
Analysts77.33
Price Target77.52 (14.51%)
Short Float %10.75%
Short Ratio5.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.41%
Min EPS beat(2)3.56%
Max EPS beat(2)19.26%
EPS beat(4)4
Avg EPS beat(4)11.06%
Min EPS beat(4)3.56%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)12.2%
EPS beat(12)10
Avg EPS beat(12)9.54%
EPS beat(16)13
Avg EPS beat(16)9.68%
Revenue beat(2)2
Avg Revenue beat(2)6.93%
Min Revenue beat(2)2.18%
Max Revenue beat(2)11.69%
Revenue beat(4)4
Avg Revenue beat(4)7.01%
Min Revenue beat(4)1.36%
Max Revenue beat(4)12.81%
Revenue beat(8)6
Avg Revenue beat(8)5.71%
Revenue beat(12)7
Avg Revenue beat(12)2.94%
Revenue beat(16)9
Avg Revenue beat(16)2.47%
PT rev (1m)1.94%
PT rev (3m)6.29%
EPS NQ rev (1m)-0.31%
EPS NQ rev (3m)1.25%
EPS NY rev (1m)1.91%
EPS NY rev (3m)1.77%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)0.61%
Revenue NY rev (1m)1.78%
Revenue NY rev (3m)1.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.02 | ||
| Fwd PE | 8.16 | ||
| P/S | 6.41 | ||
| P/FCF | 13.22 | ||
| P/OCF | 13.03 | ||
| P/B | 15.8 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.54 |
EPS(TTM)5.63
EY8.32%
EPS(NY)8.29
Fwd EY12.25%
FCF(TTM)5.12
FCFY7.57%
OCF(TTM)5.2
OCFY7.67%
SpS10.57
BVpS4.28
TBVpS-2.22
PEG (NY)0.23
PEG (5Y)N/A
Graham Number23.3
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROCE | 53.28% | ||
| ROIC | 42.77% | ||
| ROICexc | 86.79% | ||
| ROICexgc | N/A | ||
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% | ||
| FCFM | 48.47% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexgc growth 3Y-1.13%
ROICexgc growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score8
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Debt/EBITDA | 0.98 | ||
| Cap/Depr | 10.51% | ||
| Cap/Sales | 0.69% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.59% | ||
| Profit Quality | 101.16% | ||
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 | ||
| Altman-Z | 5.07 |
F-Score8
WACC7.85%
ROIC/WACC5.45
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
EPS Next Y51.29%
EPS Next 2Y40.02%
EPS Next 3Y32.08%
EPS Next 5Y17.25%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
Revenue Next Year33.82%
Revenue Next 2Y29.25%
Revenue Next 3Y23.48%
Revenue Next 5Y12.82%
EBIT growth 1Y54.59%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year61.82%
EBIT Next 3Y38.25%
EBIT Next 5Y15.57%
FCF growth 1Y70.36%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y65.76%
OCF growth 3Y16.96%
OCF growth 5YN/A
HALOZYME THERAPEUTICS INC / HALO FAQ
Can you provide the ChartMill fundamental rating for HALOZYME THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 7 / 10 to HALO.
What is the valuation status for HALO stock?
ChartMill assigns a valuation rating of 9 / 10 to HALOZYME THERAPEUTICS INC (HALO). This can be considered as Undervalued.
Can you provide the profitability details for HALOZYME THERAPEUTICS INC?
HALOZYME THERAPEUTICS INC (HALO) has a profitability rating of 8 / 10.
What is the valuation of HALOZYME THERAPEUTICS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for HALOZYME THERAPEUTICS INC (HALO) is 12.02 and the Price/Book (PB) ratio is 15.8.
How financially healthy is HALOZYME THERAPEUTICS INC?
The financial health rating of HALOZYME THERAPEUTICS INC (HALO) is 6 / 10.